Form 4 for QNCX Quince Therapeutics, Inc.
Accepted 2022-06-08 00:00:00 ET · period of report 2022-06-06 · accession 0001209191-22-035014 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-06-08 | 2022-06-06 | QNCX | McDowell Caryn Gordon | Chief Legal, Adm. Off | F - Tax | $2.86 | -6,700 | 133.3K | -5% | -$19.2K | |
| 2022-06-08 | 2022-06-06 | QNCX | McDowell Caryn Gordon | Chief Legal, Adm. Off | S - Sale | $2.86 | -10.8K | 122.5K | -8% | -$30.9K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-06-06 | F | D | 6,700 | $2.86 | 133,300 | D | — | — | (F1) Represent shares sold to satisfy tax withholding obligations that arose in connection with the vesting of 17,500 shares of Restricted Stock Units granted on March 3, 2022. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 23, 2022. (F2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.78 to $3.12, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. |
| 2 | Common | Common Stock | 2022-06-06 | S | D | 10,800 | $2.86 | 122,500 | D | — | — | (F2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.78 to $3.12, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. |